$NEUP
Neuphoria Therapeutics Inc. Stock $neup

$neup Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-K Financial Statement

#000121390024082909 Filed on September 30, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2024
Revenue	$0.00	$0.00
YoY Change		-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.667M	$8.475M
YoY Change		25.83%
% of Gross Profit
Research & Development	$1.901M	$9.418M	$9.418M
YoY Change	-38.45%	6.38%	-51.98%
% of Gross Profit
Depreciation & Amortization	$165.7K	$663.0K	$100.0K
YoY Change		-0.03%	0.0%
% of Gross Profit
Operating Expenses	$3.568M	$17.89M	$17.89M
YoY Change	-34.75%	11.54%	-8.77%
Operating Profit	-$3.568M		-$17.89M
YoY Change	-34.75%		-18.61%
Interest Expense	-$243.9K	$10.26K
YoY Change		-96.31%
% of Operating Profit
Other Income/Expense, Net	$2.631M	$2.303M	$2.313M
YoY Change	-6717.58%	-1455.37%	400.49%
Pretax Income	-$937.0K	-$15.58M	-$15.58M
YoY Change	-82.99%	-1.03%	-51.4%
Income Tax	-$132.2K	-$87.32K	-$87.32K
% Of Pretax Income
Net Earnings	-$800.0K	-$15.49M	-$15.50M
YoY Change	-85.38%	-0.94%	-51.33%
Net Earnings / Revenue
Basic Earnings Per Share	$0.00		-$0.01
Diluted Earnings Per Share	$0.00	-$0.01	-$0.01
COMMON SHARES
Basic Shares Outstanding	3.118B shares		1.798B shares
Diluted Shares Outstanding	2.808B		1.798B shares

Balance Sheet

Concept	2024 Q3	2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents	$8.100M	$12.60M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses	$231.1K	$458.8K
Receivables	$116.0K	$126.9K
Other Receivables
Total Short-Term Assets	$8.429M	$13.19M
YoY Change		-34.35%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.964K	$1.994K
YoY Change		-99.6%
Goodwill	$8.904M	$8.690M
YoY Change	3.84%	-33.58%
Intangibles	$5.302M	$5.468M
YoY Change		-10.81%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$14.49M	$14.46M
YoY Change		-36.9%
TOTAL ASSETS
Total Short-Term Assets	$8.429M	$13.19M
Total Long-Term Assets	$14.49M	$14.46M
Total Assets	$22.92M	$27.65M
YoY Change		-35.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.326M	$2.244M
YoY Change		-35.9%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.552M	$3.829M
YoY Change		-7.27%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities	$3.437K	$2.886K
YoY Change		-99.92%
Total Long-Term Liabilities	$3.437K	$2.886K
YoY Change		-99.93%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.552M	$3.829M
Total Long-Term Liabilities	$3.437K	$2.886K
Total Liabilities	$5.847M	$10.16M
YoY Change		3.07%
SHAREHOLDERS EQUITY
Retained Earnings	-$178.8M	-$178.0M
YoY Change		9.55%
Common Stock	$0.00	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$17.07M	$17.49M
YoY Change
Total Liabilities & Shareholders Equity	$22.92M	$27.65M
YoY Change		-35.71%

Cashflow Statement

Concept	2024 Q3	2024 Q2	2024
OPERATING ACTIVITIES
Net Income	-$800.0K	-$15.49M	-$15.50M
YoY Change	-85.38%	-0.94%	-51.33%
Depreciation, Depletion And Amortization	$165.7K	$663.0K	$100.0K
YoY Change		-0.03%	0.0%
Cash From Operating Activities	-$4.400M	-$5.092M	-$14.70M
YoY Change	-0.67%	-58.71%	-31.13%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-227.3K	7.685M	$15.11M
YoY Change	-137.11%	-2033.07%	171.89%
NET CHANGE
Cash From Operating Activities	-4.400M	-5.092M	-$14.70M
Cash From Investing Activities
Cash From Financing Activities	-227.3K	7.685M	$15.11M
Net Change In Cash	-4.627M	2.593M	$408.8K
YoY Change	21.22%	-120.83%	-102.67%
FREE CASH FLOW
Cash From Operating Activities	-$4.400M	-$5.092M	-$14.70M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q2	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	587762	usd
CY2023Q2	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	2456199	usd
CY2024Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	963540	usd
CY2024Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	4657832	usd
CY2024Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2886	usd
CY2023Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	14850	usd
CY2024Q2	us-gaap	Liabilities Liabilities	10158721	usd
CY2023Q2	us-gaap	Liabilities Liabilities	6552385	usd
CY2024	dei	Document Type DocumentType	10-K
CY2024	dei	Document Annual Report DocumentAnnualReport	true
CY2024	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
CY2024	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2024	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024	dei	Document Transition Report DocumentTransitionReport	false
CY2024	dei	Entity File Number EntityFileNumber	001-41157
CY2024	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	C3
CY2024	dei	Entity Address Address Line1 EntityAddressAddressLine1	200 Greenhill Road
CY2024	dei	Entity Address City Or Town EntityAddressCityOrTown	Eastwood, SA
CY2024	dei	Entity Address Country EntityAddressCountry	AU
CY2024	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	5063
CY2024	dei	City Area Code CityAreaCode	+61
CY2024	dei	Local Phone Number LocalPhoneNumber	8 8150 7400
CY2024	dei	Security12b Title Security12bTitle	American Depositary Shares
CY2024	dei	Trading Symbol TradingSymbol	BNOX
CY2024	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2024	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2024	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024	dei	Entity Small Business EntitySmallBusiness	true
CY2024	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2024	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2024	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2024	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2024	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Public Float EntityPublicFloat	13300000	usd
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	3117662864	shares
CY2024Q2	ecd	Insider Trd Policies Proc Adopted Flag InsiderTrdPoliciesProcAdoptedFlag	true
CY2024	dei	Auditor Firm AuditorFirmId	392
CY2024	dei	Auditor Name AuditorName	Wolf & Company, P.C.
CY2024	dei	Auditor Location AuditorLocation	Boston, Massachusetts
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12608109	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12103047	usd
CY2024Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	126884	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	426087	usd
CY2024Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	458765	usd
CY2023Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	797478	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	13193758	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	13326612	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1994	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2522	usd
CY2024Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	5467522	usd
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	6130253	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	216975	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	330478	usd
CY2024Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	78826	usd
CY2023Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	78897	usd
CY2024Q2	us-gaap	Goodwill Goodwill	8690018	usd
CY2023Q2	us-gaap	Goodwill Goodwill	8694186	usd
CY2024Q2	us-gaap	Assets Assets	27649093	usd
CY2023Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	78897	usd
CY2024Q2	us-gaap	Goodwill Goodwill	8690018	usd
CY2024Q2	us-gaap	Assets Assets	27649093	usd
CY2023Q2	us-gaap	Assets Assets	28562948	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2243662	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1439291	usd
CY2024Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	1463421	usd
CY2023Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	1185567	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	121990	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	113930	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3829073	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2738788	usd
CY2023Q2	us-gaap	Assets Assets	28562948	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2243662	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1439291	usd
CY2023Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	1185567	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	121990	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3829073	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2738788	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	117628	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	239835	usd
CY2024Q2	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	587762	usd
CY2023Q2	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	2456199	usd
CY2024Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	963540	usd
CY2023Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1102713	usd
CY2024Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	4657832	usd
CY2024Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2886	usd
CY2023Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	14850	usd
CY2023Q2	us-gaap	Liabilities Liabilities	6552385	usd
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2384539964	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2384539964	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1468735424	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1468735424	shares
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	198481038	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	187554251	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	117628	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	239835	usd
CY2023Q2	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	2456199	usd
CY2024Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	963540	usd
CY2024Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	4657832	usd
CY2024Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2886	usd
CY2023Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	14850	usd
CY2024Q2	us-gaap	Liabilities Liabilities	10158721	usd
CY2023Q2	us-gaap	Liabilities Liabilities	6552385	usd
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2384539964	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2384539964	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1468735424	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1468735424	shares
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	198481038	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	187554251	usd
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3013595	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3058783	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-162484905	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	17490372	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	22010563	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	27649093	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	28562948	usd
CY2024	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9417785	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13071705	usd
CY2024	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8474591	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8911271	usd
CY2024	us-gaap	Operating Expenses OperatingExpenses	17892376	usd
CY2024	us-gaap	Operating Income Loss OperatingIncomeLoss	-17892376	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-21982976	usd
CY2024	us-gaap	Investment Income Interest InvestmentIncomeInterest	220097	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	323158	usd
CY2024	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-209842	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	308852	usd
CY2024	bnox	Research And Development Incentive Award ResearchAndDevelopmentIncentiveAward	-95215	usd
CY2023	bnox	Research And Development Incentive Award ResearchAndDevelopmentIncentiveAward	-422742	usd
CY2024	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	2207420	usd
CY2023	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-592627	usd
CY2024	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2312890	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	462125	usd
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-15579486	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21520851	usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-87320	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-139174	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-15492166	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-21381677	usd
CY2024	us-gaap	Foreign Currency Transaction Gain Loss Unrealized After Tax ForeignCurrencyTransactionGainLossUnrealizedAfterTax	45188	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Unrealized After Tax ForeignCurrencyTransactionGainLossUnrealizedAfterTax	-1036633	usd
CY2024	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	45188	usd
CY2024	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15446978	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-22418310	usd
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2384539964	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2384539964	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1468735424	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1468735424	shares
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	198481038	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	187554251	usd
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3013595	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3058783	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-177977071	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-162484905	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	17490372	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	22010563	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	27649093	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	28562948	usd
CY2024	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9417785	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13071705	usd
CY2024	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8474591	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8911271	usd
CY2024	us-gaap	Operating Expenses OperatingExpenses	17892376	usd
CY2024	us-gaap	Operating Income Loss OperatingIncomeLoss	-17892376	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-21982976	usd
CY2024	us-gaap	Investment Income Interest InvestmentIncomeInterest	220097	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	323158	usd
CY2024	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-209842	usd
CY2024	bnox	Research And Development Incentive Award ResearchAndDevelopmentIncentiveAward	-95215	usd
CY2023	bnox	Research And Development Incentive Award ResearchAndDevelopmentIncentiveAward	-422742	usd
CY2024	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	2207420	usd
CY2023	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-592627	usd
CY2024	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2312890	usd
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-15579486	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21520851	usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-87320	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-139174	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-15492166	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-21381677	usd
CY2024	us-gaap	Foreign Currency Transaction Gain Loss Unrealized After Tax ForeignCurrencyTransactionGainLossUnrealizedAfterTax	45188	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Unrealized After Tax ForeignCurrencyTransactionGainLossUnrealizedAfterTax	-1036633	usd
CY2024	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	45188	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1036633	usd
CY2024	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15446978	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-22418310	usd
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1797606532	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1468735424	shares
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	39225113	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1100000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3858451	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1345309	usd
CY2023	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	1036633	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-21381677	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	22010563	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3058783	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-177977071	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-162484905	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	17490372	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	22010563	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	27649093	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	28562948	usd
CY2024	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9417785	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13071705	usd
CY2024	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8474591	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8911271	usd
CY2024	us-gaap	Operating Expenses OperatingExpenses	17892376	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	21982976	usd
CY2024	us-gaap	Operating Income Loss OperatingIncomeLoss	-17892376	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-21982976	usd
CY2024	us-gaap	Investment Income Interest InvestmentIncomeInterest	220097	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	323158	usd
CY2024	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-209842	usd
CY2024	bnox	Research And Development Incentive Award ResearchAndDevelopmentIncentiveAward	-95215	usd
CY2024	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	2207420	usd
CY2023	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-592627	usd
CY2024	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2312890	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	462125	usd
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-15579486	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21520851	usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-87320	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-139174	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-21381677	usd
CY2024	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	45188	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1036633	usd
CY2024	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15446978	usd
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1797606532	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1468735424	shares
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	39225113	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1100000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3858451	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1345309	usd
CY2023	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	1036633	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-21381677	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	22010563	usd
CY2024	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1300000	usd
CY2024	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10111979	usd
CY2024	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	814808	usd
CY2024	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	-45188	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-15492166	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	17490372	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-15492166	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-21381677	usd
CY2024	us-gaap	Share Based Compensation ShareBasedCompensation	814808	usd
CY2024	us-gaap	Depreciation And Amortization DepreciationAndAmortization	662991	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	663192	usd
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-15579486	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21520851	usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-87320	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-139174	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-15492166	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-21381677	usd
CY2024	us-gaap	Foreign Currency Transaction Gain Loss Unrealized After Tax ForeignCurrencyTransactionGainLossUnrealizedAfterTax	45188	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Unrealized After Tax ForeignCurrencyTransactionGainLossUnrealizedAfterTax	-1036633	usd
CY2024	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	45188	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1036633	usd
CY2024	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15446978	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-22418310	usd
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1797606532	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1468735424	shares
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	39225113	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1100000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3858451	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1345309	usd
CY2023	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	1036633	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-21381677	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	22010563	usd
CY2024	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1300000	usd
CY2024	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10111979	usd
CY2024	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	814808	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-15492166	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	17490372	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-21381677	usd
CY2024	us-gaap	Share Based Compensation ShareBasedCompensation	814808	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	1345309	usd
CY2024	us-gaap	Depreciation And Amortization DepreciationAndAmortization	662991	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	663192	usd
CY2024	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-113503	usd
CY2023	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-115123	usd
CY2024	bnox	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	-1868437	usd
CY2023	bnox	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	592627	usd
CY2024	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	27350	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	556782	usd
CY2024	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-299203	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-4137199	usd
CY2024	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-338713	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-173975	usd
CY2024	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	804371	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	374176	usd
CY2024	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	277854	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	138079	usd
CY2024	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-114147	usd
CY2024	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-139173	usd
CY2023	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-139173	usd
CY2024	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-11964	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	8041	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14680777	usd
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1797606532	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1468735424	shares
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	39225113	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1100000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3858451	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1345309	usd
CY2023	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	1036633	usd
CY2024	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1300000	usd
CY2024	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10111979	usd
CY2024	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	814808	usd
CY2024	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	-45188	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	17490372	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-15492166	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-21381677	usd
CY2024	us-gaap	Share Based Compensation ShareBasedCompensation	814808	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	1345309	usd
CY2024	us-gaap	Depreciation And Amortization DepreciationAndAmortization	662991	usd
CY2024	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-113503	usd
CY2023	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-115123	usd
CY2024	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-338983	usd
CY2024	bnox	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	-1868437	usd
CY2023	bnox	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	592627	usd
CY2024	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	27350	usd
CY2024	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-299203	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-4137199	usd
CY2024	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	804371	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	374176	usd
CY2024	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	277854	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	138079	usd
CY2024	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-114147	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-107808	usd
CY2024	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-139173	usd
CY2023	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-139173	usd
CY2024	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-11964	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	8041	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14680777	usd
CY2024	bnox	Proceeds From Saleof Sharesand Prefunded Warrants ProceedsFromSaleofSharesandPrefundedWarrants	10111979	usd
CY2023	bnox	Proceeds From Sale Of Ads Shares ProceedsFromSaleOfADSShares	3858451	usd
CY2024	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	4996815	usd
CY2024	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	15108794	usd
CY2024	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	76974	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-243822	usd
CY2024	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	428017	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-10779269	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12181944	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23205035	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12686935	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12181944	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12608109	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12103047	usd
CY2024Q2	us-gaap	Restricted Cash RestrictedCash	78826	usd
CY2023Q2	us-gaap	Restricted Cash RestrictedCash	78897	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12686935	usd
CY2024	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1300000	usd
CY2024	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10111979	usd
CY2024	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	814808	usd
CY2024	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	-45188	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	17490372	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-15492166	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-21381677	usd
CY2024	us-gaap	Share Based Compensation ShareBasedCompensation	814808	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	1345309	usd
CY2024	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-113503	usd
CY2023	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-115123	usd
CY2024	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-338983	usd
CY2024	bnox	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	-1868437	usd
CY2023	bnox	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	592627	usd
CY2024	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	27350	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	556782	usd
CY2024	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-299203	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-4137199	usd
CY2024	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-338713	usd
CY2024	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	804371	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	374176	usd
CY2024	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	277854	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	138079	usd
CY2024	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-114147	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-107808	usd
CY2024	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-139173	usd
CY2023	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-139173	usd
CY2024	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-11964	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	8041	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14680777	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14637720	usd
CY2024	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1300000	usd
CY2024	bnox	Proceeds From Saleof Sharesand Prefunded Warrants ProceedsFromSaleofSharesandPrefundedWarrants	10111979	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1100000	usd
CY2023	bnox	Proceeds From Sale Of Ads Shares ProceedsFromSaleOfADSShares	3858451	usd
CY2024	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	4996815	usd
CY2024	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	15108794	usd
CY2024	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	76974	usd
CY2024	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	428017	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-10779269	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23205035	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12686935	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12181944	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12608109	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12103047	usd
CY2024Q2	us-gaap	Restricted Cash RestrictedCash	78826	usd
CY2023Q2	us-gaap	Restricted Cash RestrictedCash	78897	usd
CY2024	us-gaap	Interest Paid Net InterestPaidNet	31516	usd
CY2024	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	51853	usd
CY2024	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-113503	usd
CY2023	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-115123	usd
CY2024	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-338983	usd
CY2024	bnox	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	-1868437	usd
CY2023	bnox	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	592627	usd
CY2024	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	27350	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	556782	usd
CY2024	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-299203	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-4137199	usd
CY2024	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	804371	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	374176	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	138079	usd
CY2024	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-114147	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-107808	usd
CY2024	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-139173	usd
CY2023	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-139173	usd
CY2024	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-11964	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	8041	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14680777	usd
CY2024	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1300000	usd
CY2024	bnox	Proceeds From Saleof Sharesand Prefunded Warrants ProceedsFromSaleofSharesandPrefundedWarrants	10111979	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1100000	usd
CY2023	bnox	Proceeds From Sale Of Ads Shares ProceedsFromSaleOfADSShares	3858451	usd
CY2024	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	4996815	usd
CY2024	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	15108794	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3858451	usd
CY2024	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	76974	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-243822	usd
CY2024	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	428017	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-10779269	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23205035	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12686935	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12181944	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12608109	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12103047	usd
CY2024Q2	us-gaap	Restricted Cash RestrictedCash	78826	usd
CY2023Q2	us-gaap	Restricted Cash RestrictedCash	78897	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12686935	usd
CY2024Q2	bnox	Working Capital Deficit WorkingCapitalDeficit	9400000	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-15500000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-21400000	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14700000	usd
CY2024	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1300000	usd
CY2024	bnox	Proceeds From Saleof Sharesand Prefunded Warrants ProceedsFromSaleofSharesandPrefundedWarrants	10111979	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1100000	usd
CY2023	bnox	Proceeds From Sale Of Ads Shares ProceedsFromSaleOfADSShares	3858451	usd
CY2024	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	4996815	usd
CY2024	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	15108794	usd
CY2024	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	76974	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-243822	usd
CY2024	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	428017	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-10779269	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12686935	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12181944	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12608109	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12103047	usd
CY2024Q2	us-gaap	Restricted Cash RestrictedCash	78826	usd
CY2023Q2	us-gaap	Restricted Cash RestrictedCash	78897	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12686935	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12181944	usd
CY2024	us-gaap	Interest Paid Net InterestPaidNet	31516	usd
CY2024	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	51853	usd
CY2024Q2	bnox	Working Capital Deficit WorkingCapitalDeficit	9400000	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12600000	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-15500000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-21400000	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14700000	usd
CY2024	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Use of Estimates</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The preparation of the Company’s consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosure of revenue, expenses, and certain assets and liabilities at the balance sheet date. Such estimates include the performance obligations under the Company’s collaboration agreements, the collectability of receivables, impairment evaluation for goodwill and intangible assets, and the fair values of contingent consideration and warrants. Actual results may differ from such estimates.</span></p>
CY2024	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12181944	usd
CY2024	us-gaap	Interest Paid Net InterestPaidNet	31516	usd
CY2024	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	51853	usd
CY2024Q2	bnox	Working Capital Deficit WorkingCapitalDeficit	9400000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-178000000	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12600000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-21400000	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14700000	usd
CY2024	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
CY2024Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	100000	usd
CY2024Q2	bnox	Working Capital Deficit WorkingCapitalDeficit	9400000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-178000000	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12600000	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-15500000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-21400000	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14700000	usd
CY2024	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
CY2024Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	100000	usd
CY2023Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	100000	usd
CY2024	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Concentration of Credit Risk</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. The Company’s cash and cash equivalents and restricted cash are held by financial institutions that management believes are of high credit quality. Amounts on deposit may at times exceed federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents of restricted cash and its accounts are monitored by management to mitigate risk. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash, cash equivalents, and restricted cash, and bond issuers.</p>
CY2024	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Use of Estimates</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The preparation of the Company’s consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosure of revenue, expenses, and certain assets and liabilities at the balance sheet date. Such estimates include the performance obligations under the Company’s collaboration agreements, the collectability of receivables, impairment evaluation for goodwill and intangible assets, and the fair values of contingent consideration and warrants. Actual results may differ from such estimates.</span></p>
CY2024	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
CY2024Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	100000	usd
CY2023Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	100000	usd
CY2024Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	100000	usd
CY2024	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	pure
CY2024	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	pure
CY2024	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	pure
CY2024Q2	bnox	Research And Development Incentives Receivable ResearchAndDevelopmentIncentivesReceivable	96154	usd
CY2023Q2	bnox	Research And Development Incentives Receivable ResearchAndDevelopmentIncentivesReceivable	416072	usd
CY2024Q2	bnox	Gst Receivables GSTReceivables	30444	usd
CY2023Q2	bnox	Gst Receivables GSTReceivables	9758	usd
CY2024Q2	us-gaap	Interest Receivable Current InterestReceivableCurrent	286	usd
CY2023Q2	us-gaap	Interest Receivable Current InterestReceivableCurrent	257	usd
CY2024Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	126884	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	426087	usd
CY2024Q2	bnox	Research And Development Incentives Receivable ResearchAndDevelopmentIncentivesReceivable	96154	usd
CY2024Q2	bnox	Gst Receivables GSTReceivables	30444	usd
CY2024Q2	us-gaap	Interest Receivable Current InterestReceivableCurrent	286	usd
CY2023Q2	us-gaap	Interest Receivable Current InterestReceivableCurrent	257	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	426087	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	47759	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	45722	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	45237	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1994	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2522	usd
CY2023	us-gaap	Depreciation Depreciation	100000	usd
CY2021Q2	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P5Y
CY2024	bnox	Lease Payments Percenatage LeasePaymentsPercenatage	0.03	pure
CY2024Q2	bnox	Research And Development Incentives Receivable ResearchAndDevelopmentIncentivesReceivable	96154	usd
CY2023Q2	bnox	Research And Development Incentives Receivable ResearchAndDevelopmentIncentivesReceivable	416072	usd
CY2024Q2	bnox	Gst Receivables GSTReceivables	30444	usd
CY2024Q2	us-gaap	Interest Receivable Current InterestReceivableCurrent	286	usd
CY2024Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	126884	usd
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	47716	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	47759	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	45722	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	45237	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1994	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2522	usd
CY2023	us-gaap	Depreciation Depreciation	100000	usd
CY2024	us-gaap	Depreciation Depreciation	100000	usd
CY2024	bnox	Lease Payments Percenatage LeasePaymentsPercenatage	0.03	pure
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	121990	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	113930	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	117628	usd
CY2024Q2	bnox	Research And Development Incentives Receivable ResearchAndDevelopmentIncentivesReceivable	96154	usd
CY2023Q2	bnox	Research And Development Incentives Receivable ResearchAndDevelopmentIncentivesReceivable	416072	usd
CY2024Q2	bnox	Gst Receivables GSTReceivables	30444	usd
CY2024Q2	us-gaap	Interest Receivable Current InterestReceivableCurrent	286	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	426087	usd
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	47716	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	45237	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1994	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2522	usd
CY2024	us-gaap	Depreciation Depreciation	100000	usd
CY2021Q2	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P5Y
CY2024Q2	us-gaap	Lessor Operating Lease Renewal Term LessorOperatingLeaseRenewalTerm	P1Y
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	216975	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	330478	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	121990	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	113930	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	117628	usd
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	47716	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	47759	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	45722	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	45237	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1994	usd
CY2021Q2	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P5Y
CY2024	bnox	Lease Payments Percenatage LeasePaymentsPercenatage	0.03	pure
CY2024Q2	us-gaap	Lessor Operating Lease Renewal Term LessorOperatingLeaseRenewalTerm	P1Y
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	216975	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	121990	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	113930	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	117628	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	239618	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	353765	usd
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.035	pure
CY2024Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y
CY2024	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	61110	usd
CY2023	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	64728	usd
CY2024	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	68296	usd
CY2023	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	71348	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	136076	usd
CY2024Q2	us-gaap	Lessor Operating Lease Renewal Term LessorOperatingLeaseRenewalTerm	P1Y
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	216975	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	330478	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	121990	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	113930	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	117628	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	239835	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	239618	usd
CY2024	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	61110	usd
CY2024	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	68296	usd
CY2023	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	71348	usd
CY2024	us-gaap	Operating Lease Cost OperatingLeaseCost	129406	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	136076	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	193406	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	182854	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	376260	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	136642	usd
CY2023	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	179930	usd
CY2024	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	4168	usd
CY2024	bnox	Post Tax Discount Rate Percentage PostTaxDiscountRatePercentage	0.20	pure
CY2023	bnox	Post Tax Discount Rate Percentage PostTaxDiscountRatePercentage	0.24	pure
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	239835	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	239618	usd
CY2024	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	61110	usd
CY2024	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	68296	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	136076	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	193406	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	182854	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	376260	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	136642	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	239618	usd
CY2022Q2	us-gaap	Goodwill Goodwill	8874116	usd
CY2023	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	179930	usd
CY2023Q2	us-gaap	Goodwill Goodwill	8694186	usd
CY2024Q2	us-gaap	Goodwill Goodwill	8690018	usd
CY2024	bnox	Post Tax Discount Rate Percentage PostTaxDiscountRatePercentage	0.20	pure
CY2023	bnox	Post Tax Discount Rate Percentage PostTaxDiscountRatePercentage	0.24	pure
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	239835	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	239618	usd
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.035	pure
CY2024	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	61110	usd
CY2023	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	64728	usd
CY2024	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	68296	usd
CY2023	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	71348	usd
CY2024	us-gaap	Operating Lease Cost OperatingLeaseCost	129406	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	136076	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	193406	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	182854	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	376260	usd
CY2022Q2	us-gaap	Goodwill Goodwill	8874116	usd
CY2023Q2	us-gaap	Goodwill Goodwill	8694186	usd
CY2024	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	4168	usd
CY2024Q2	us-gaap	Goodwill Goodwill	8690018	usd
CY2024	bnox	Post Tax Discount Rate Percentage PostTaxDiscountRatePercentage	0.20	pure
CY2023	bnox	Post Tax Discount Rate Percentage PostTaxDiscountRatePercentage	0.24	pure
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	193406	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	182854	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	376260	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	136642	usd
CY2023	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	179930	usd
CY2023Q2	us-gaap	Goodwill Goodwill	8694186	usd
CY2024	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	4168	usd
CY2024Q2	us-gaap	Goodwill Goodwill	8690018	usd
CY2024	bnox	Post Tax Discount Rate Percentage PostTaxDiscountRatePercentage	0.20	pure
CY2023	bnox	Post Tax Discount Rate Percentage PostTaxDiscountRatePercentage	0.24	pure
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	0	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	0	usd
CY2024Q2	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P20Y
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	0	usd
CY2024Q2	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P20Y
CY2024Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	648858	usd
CY2023Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	573149	usd
CY2024Q2	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	311172	usd
CY2024Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	241157	usd
CY2023Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	367361	usd
CY2024Q2	bnox	Research And Development Expenses ResearchAndDevelopmentExpenses	134910	usd
CY2024Q2	bnox	Consulting Fees ConsultingFees	56623	usd
CY2024Q2	bnox	Eda Loan EDALoan	33120	usd
CY2024Q2	bnox	Facility Restoration Costs FacilityRestorationCosts	19872	usd
CY2024Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	17709	usd
CY2023Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	39405	usd
CY2023Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	1185567	usd
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1000	aud
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	0	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	0	usd
CY2024Q2	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P20Y
CY2024Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	648858	usd
CY2024Q2	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	311172	usd
CY2024Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	241157	usd
CY2024Q2	bnox	Research And Development Expenses ResearchAndDevelopmentExpenses	134910	usd
CY2023Q2	bnox	Research And Development Expenses ResearchAndDevelopmentExpenses	49501	usd
CY2024Q2	bnox	Consulting Fees ConsultingFees	56623	usd
CY2023Q2	bnox	Consulting Fees ConsultingFees	103111	usd
CY2024Q2	bnox	Eda Loan EDALoan	33120	usd
CY2023Q2	bnox	Eda Loan EDALoan	33150	usd
CY2024Q2	bnox	Facility Restoration Costs FacilityRestorationCosts	19872	usd
CY2024Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	17709	usd
CY2023Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	39405	usd
CY2023Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	1185567	usd
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1000	aud
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P5Y
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	0	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	0	usd
CY2024Q2	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P20Y
CY2024Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	648858	usd
CY2023Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	573149	usd
CY2024Q2	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	311172	usd
CY2024Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	241157	usd
CY2024Q2	bnox	Research And Development Expenses ResearchAndDevelopmentExpenses	134910	usd
CY2023Q2	bnox	Research And Development Expenses ResearchAndDevelopmentExpenses	49501	usd
CY2024Q2	bnox	Consulting Fees ConsultingFees	56623	usd
CY2023Q2	bnox	Consulting Fees ConsultingFees	103111	usd
CY2024Q2	bnox	Eda Loan EDALoan	33120	usd
CY2023Q2	bnox	Eda Loan EDALoan	33150	usd
CY2024Q2	bnox	Facility Restoration Costs FacilityRestorationCosts	19872	usd
CY2024Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	17709	usd
CY2023Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	1185567	usd
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P5Y
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y4M24D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	79056617	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.16
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y11M4D
CY2024Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	648858	usd
CY2023Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	573149	usd
CY2024Q2	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	311172	usd
CY2024Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	241157	usd
CY2023Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	367361	usd
CY2024Q2	bnox	Research And Development Expenses ResearchAndDevelopmentExpenses	134910	usd
CY2023Q2	bnox	Research And Development Expenses ResearchAndDevelopmentExpenses	49501	usd
CY2024Q2	bnox	Consulting Fees ConsultingFees	56623	usd
CY2023Q2	bnox	Consulting Fees ConsultingFees	103111	usd
CY2024Q2	bnox	Eda Loan EDALoan	33120	usd
CY2023Q2	bnox	Eda Loan EDALoan	33150	usd
CY2024Q2	bnox	Facility Restoration Costs FacilityRestorationCosts	19872	usd
CY2023Q2	bnox	Facility Restoration Costs FacilityRestorationCosts	19890	usd
CY2024Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	17709	usd
CY2023Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	1185567	usd
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1000	aud
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	79056617	shares
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y11M4D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	43100348	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.04
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	3500000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.05
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Other Increases Decreases In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod	-1445650	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.16
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y11M4D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	43100348	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.04
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	3500000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.05
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Other Increases Decreases In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod	-1445650	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Other Share Increase Decrease In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice	0.39
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	117211315	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.12
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y10M6D
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	5839385	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	110449330	shares
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y2M4D
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	90969949	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.13
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y10M6D
CY2024Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	100000	usd
CY2024	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	800000	usd
CY2023	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	1300000	usd
CY2024	us-gaap	Common Stock Conversion Basis CommonStockConversionBasis	1:1
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	79056617	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.16
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y11M4D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	43100348	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.04
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.05
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Other Increases Decreases In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod	-1445650	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.12
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y10M6D
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	5839385	shares
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.06
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Other Increases Decreases In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod	-922600	shares
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Other Share Increase Decrease In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice	0.22
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	110449330	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.12
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y2M4D
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	90969949	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.13
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y10M6D
CY2024Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	100000	usd
CY2024	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	800000	usd
CY2023	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	1300000	usd
CY2024	us-gaap	Common Stock Conversion Basis CommonStockConversionBasis	1:1
CY2023	us-gaap	Common Stock Conversion Basis CommonStockConversionBasis	1:1
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	43100348	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.04
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	3500000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.05
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Other Increases Decreases In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod	-1445650	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.12
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y10M6D
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	5839385	shares
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.06
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Other Increases Decreases In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod	-922600	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	110449330	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.12
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y2M4D
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.13
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y10M6D
CY2024Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	100000	usd
CY2024	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	800000	usd
CY2023	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	1300000	usd
CY2024	us-gaap	Common Stock Conversion Basis CommonStockConversionBasis	1:1
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.12
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y10M6D
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	5839385	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.12
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y2M4D
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	90969949	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.13
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y10M6D
CY2024Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	100000	usd
CY2024	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	800000	usd
CY2023	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	1300000	usd
CY2024	us-gaap	Common Stock Conversion Basis CommonStockConversionBasis	1:1
CY2023	us-gaap	Common Stock Conversion Basis CommonStockConversionBasis	1:1
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-1819496	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-1322142	usd
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-13759990	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-20198709	usd
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-15579486	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21520851	usd
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-1819496	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-1322142	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-20198709	usd
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-15579486	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21520851	usd
CY2024	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	51853	usd
CY2024	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	51853	usd
CY2024	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-118946	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-124577	usd
CY2024	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-20227	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-14597	usd
CY2024	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-3999422	usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	4634968	usd
CY2024	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	3999422	usd
CY2023	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	-4634968	usd
CY2024	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-139173	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-139174	usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-87320	usd
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-15579486	usd
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-1819496	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-1322142	usd
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-13759990	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-20198709	usd
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-15579486	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21520851	usd
CY2024	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	51853	usd
CY2024	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	51853	usd
CY2024	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-118946	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-124577	usd
CY2024	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-20227	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-14597	usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	4634968	usd
CY2023	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	-4634968	usd
CY2024	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-139173	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-139174	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-139174	usd
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-15579486	usd
CY2024	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-3894872	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.25	pure
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-5380213	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.25	pure
CY2024	bnox	Effective Income Tax Rate Reconciliation Exempt Income From Government Assistance Rd EffectiveIncomeTaxRateReconciliationExemptIncomeFromGovernmentAssistanceRD	-23804	usd
CY2024	bnox	Effective Income Tax Rate Reconciliation Exempt Income From Government Assistance Rd Percentage EffectiveIncomeTaxRateReconciliationExemptIncomeFromGovernmentAssistanceRDPercentage	0.002	pure
CY2023	bnox	Effective Income Tax Rate Reconciliation Exempt Income From Government Assistance Rd EffectiveIncomeTaxRateReconciliationExemptIncomeFromGovernmentAssistanceRD	-105686	usd
CY2023	bnox	Effective Income Tax Rate Reconciliation Exempt Income From Government Assistance Rd Percentage EffectiveIncomeTaxRateReconciliationExemptIncomeFromGovernmentAssistanceRDPercentage	0.005	pure
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-1819496	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-1322142	usd
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-13759990	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-20198709	usd
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-15579486	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21520851	usd
CY2024	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	51853	usd
CY2024	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	51853	usd
CY2024	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-118946	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-124577	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-14597	usd
CY2024	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-3999422	usd
CY2024	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	3999422	usd
CY2023	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	-4634968	usd
CY2024	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-139173	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-139174	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-139174	usd
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-15579486	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21520851	usd
CY2024	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-3894872	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.25	pure
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-5380213	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.25	pure
CY2024	bnox	Effective Income Tax Rate Reconciliation Exempt Income From Government Assistance Rd EffectiveIncomeTaxRateReconciliationExemptIncomeFromGovernmentAssistanceRD	-23804	usd
CY2024	bnox	Effective Income Tax Rate Reconciliation Exempt Income From Government Assistance Rd Percentage EffectiveIncomeTaxRateReconciliationExemptIncomeFromGovernmentAssistanceRDPercentage	0.002	pure
CY2023	bnox	Effective Income Tax Rate Reconciliation Exempt Income From Government Assistance Rd EffectiveIncomeTaxRateReconciliationExemptIncomeFromGovernmentAssistanceRD	-105686	usd
CY2023	bnox	Effective Income Tax Rate Reconciliation Exempt Income From Government Assistance Rd Percentage EffectiveIncomeTaxRateReconciliationExemptIncomeFromGovernmentAssistanceRDPercentage	0.005	pure
CY2024	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	-460297	usd
CY2024	bnox	Effective Income Tax Rate Reconciliation Net Gain Arising On Changes In Fair Value Of Contingent Consideration Percentage EffectiveIncomeTaxRateReconciliationNetGainArisingOnChangesInFairValueOfContingentConsiderationPercentage	0.03	pure
CY2023	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	166417	usd
CY2023	bnox	Effective Income Tax Rate Reconciliation Net Gain Arising On Changes In Fair Value Of Contingent Consideration Percentage EffectiveIncomeTaxRateReconciliationNetGainArisingOnChangesInFairValueOfContingentConsiderationPercentage	-0.008	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	104757	usd
CY2024	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	51853	usd
CY2024	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	51853	usd
CY2024	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-118946	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-124577	usd
CY2024	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-20227	usd
CY2024	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-3999422	usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	4634968	usd
CY2024	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	3999422	usd
CY2023	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	-4634968	usd
CY2024	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-139173	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-139174	usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-87320	usd
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-15579486	usd
CY2024	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-3894872	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.25	pure
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-5380213	usd
CY2024	bnox	Effective Income Tax Rate Reconciliation Exempt Income From Government Assistance Rd EffectiveIncomeTaxRateReconciliationExemptIncomeFromGovernmentAssistanceRD	-23804	usd
CY2024	bnox	Effective Income Tax Rate Reconciliation Exempt Income From Government Assistance Rd Percentage EffectiveIncomeTaxRateReconciliationExemptIncomeFromGovernmentAssistanceRDPercentage	0.002	pure
CY2024	bnox	Effective Income Tax Rate Reconciliation Net Gain Arising On Changes In Fair Value Of Contingent Consideration Percentage EffectiveIncomeTaxRateReconciliationNetGainArisingOnChangesInFairValueOfContingentConsiderationPercentage	0.03	pure
CY2023	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	166417	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	104757	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.007	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	320741	usd
CY2024	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	-54721	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	-0.003	pure
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	-242956	usd
CY2024	bnox	Effective Income Tax Rate Reconciliation Project Costs EffectiveIncomeTaxRateReconciliationProjectCosts	-242820	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.016	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.009	pure
CY2024	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	51853	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	0.004	pure
CY2024	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-42212	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21520851	usd
CY2024	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-3894872	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.25	pure
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-5380213	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.25	pure
CY2024	bnox	Effective Income Tax Rate Reconciliation Exempt Income From Government Assistance Rd EffectiveIncomeTaxRateReconciliationExemptIncomeFromGovernmentAssistanceRD	-23804	usd
CY2023	bnox	Effective Income Tax Rate Reconciliation Exempt Income From Government Assistance Rd EffectiveIncomeTaxRateReconciliationExemptIncomeFromGovernmentAssistanceRD	-105686	usd
CY2023	bnox	Effective Income Tax Rate Reconciliation Exempt Income From Government Assistance Rd Percentage EffectiveIncomeTaxRateReconciliationExemptIncomeFromGovernmentAssistanceRDPercentage	0.005	pure
CY2024	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	-460297	usd
CY2024	bnox	Effective Income Tax Rate Reconciliation Net Gain Arising On Changes In Fair Value Of Contingent Consideration Percentage EffectiveIncomeTaxRateReconciliationNetGainArisingOnChangesInFairValueOfContingentConsiderationPercentage	0.03	pure
CY2023	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	166417	usd
CY2023	bnox	Effective Income Tax Rate Reconciliation Net Gain Arising On Changes In Fair Value Of Contingent Consideration Percentage EffectiveIncomeTaxRateReconciliationNetGainArisingOnChangesInFairValueOfContingentConsiderationPercentage	-0.008	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	104757	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.007	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	320741	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.015	pure
CY2024	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	-54721	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	-0.003	pure
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	-242956	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	-0.011	pure
CY2024	bnox	Effective Income Tax Rate Reconciliation Project Costs EffectiveIncomeTaxRateReconciliationProjectCosts	-242820	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.016	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.009	pure
CY2024	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	51853	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	0.004	pure
CY2024	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-42212	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.003	pure
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	20692	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.001	pure
CY2024	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	3999422	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.257	pure
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4634968	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.215	pure
CY2024	bnox	Effective Income Tax Rate Reconciliation Decrease To State Tax Benefit EffectiveIncomeTaxRateReconciliationDecreaseToStateTaxBenefit	357738	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.023	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.007	pure
CY2024	bnox	Effective Income Tax Rate Reconciliation Other EffectiveIncomeTaxRateReconciliationOther	-8194	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.001	pure
CY2023	bnox	Effective Income Tax Rate Reconciliation Other EffectiveIncomeTaxRateReconciliationOther	-959	usd
CY2024	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.006	pure
CY2023Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	408919	usd
CY2024Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	25723125	usd
CY2023Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	21911771	usd
CY2024Q2	bnox	Deferred Tax Assets Capital Expenditures Not Deducted DeferredTaxAssetsCapitalExpendituresNotDeducted	1168484	usd
CY2023Q2	bnox	Deferred Tax Assets Capital Expenditures Not Deducted DeferredTaxAssetsCapitalExpendituresNotDeducted	889777	usd
CY2024Q2	bnox	Deferred Tax Assets Tax Deferred Expense Provision For Leave DeferredTaxAssetsTaxDeferredExpenseProvisionForLeave	81513	usd
CY2023Q2	bnox	Deferred Tax Assets Tax Deferred Expense Provision For Leave DeferredTaxAssetsTaxDeferredExpenseProvisionForLeave	77550	usd
CY2024Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	56122	usd
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	59688	usd
CY2024Q2	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	509498	usd
CY2023Q2	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	541841	usd
CY2024Q2	bnox	Deferred Tax Assets Warrant Costs DeferredTaxAssetsWarrantCosts	164725	usd
CY2024Q2	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	32061	usd
CY2023Q2	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	32061	usd
CY2024	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	-460297	usd
CY2024	bnox	Effective Income Tax Rate Reconciliation Net Gain Arising On Changes In Fair Value Of Contingent Consideration Percentage EffectiveIncomeTaxRateReconciliationNetGainArisingOnChangesInFairValueOfContingentConsiderationPercentage	0.03	pure
CY2023	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	166417	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	104757	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.007	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	320741	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.015	pure
CY2024	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	-54721	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	-242956	usd
CY2024	bnox	Effective Income Tax Rate Reconciliation Project Costs EffectiveIncomeTaxRateReconciliationProjectCosts	-242820	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.009	pure
CY2024	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	51853	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	0.004	pure
CY2024	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-42212	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.003	pure
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	20692	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.001	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.257	pure
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4634968	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.215	pure
CY2024	bnox	Effective Income Tax Rate Reconciliation Decrease To State Tax Benefit EffectiveIncomeTaxRateReconciliationDecreaseToStateTaxBenefit	357738	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.023	pure
CY2023	bnox	Effective Income Tax Rate Reconciliation Decrease To State Tax Benefit EffectiveIncomeTaxRateReconciliationDecreaseToStateTaxBenefit	152402	usd
CY2024	bnox	Effective Income Tax Rate Reconciliation Other EffectiveIncomeTaxRateReconciliationOther	-8194	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.001	pure
CY2023	bnox	Effective Income Tax Rate Reconciliation Other EffectiveIncomeTaxRateReconciliationOther	-959	usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-87320	usd
CY2024	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.006	pure
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-139174	usd
CY2024Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	646812	usd
CY2023Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	408919	usd
CY2024Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	25723125	usd
CY2023Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	21911771	usd
CY2024Q2	bnox	Deferred Tax Assets Capital Expenditures Not Deducted DeferredTaxAssetsCapitalExpendituresNotDeducted	1168484	usd
CY2023Q2	bnox	Deferred Tax Assets Capital Expenditures Not Deducted DeferredTaxAssetsCapitalExpendituresNotDeducted	889777	usd
CY2024Q2	bnox	Deferred Tax Assets Tax Deferred Expense Provision For Leave DeferredTaxAssetsTaxDeferredExpenseProvisionForLeave	81513	usd
CY2023Q2	bnox	Deferred Tax Assets Tax Deferred Expense Provision For Leave DeferredTaxAssetsTaxDeferredExpenseProvisionForLeave	77550	usd
CY2024Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	56122	usd
CY2024Q2	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	509498	usd
CY2023Q2	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	541841	usd
CY2024Q2	bnox	Deferred Tax Assets Warrant Costs DeferredTaxAssetsWarrantCosts	164725	usd
CY2024Q2	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	32061	usd
CY2023Q2	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	32061	usd
CY2023Q2	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	29224	usd
CY2024Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	69730	usd
CY2023Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	102756	usd
CY2024Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	28452070	usd
CY2023Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	24053587	usd
CY2024Q2	us-gaap	Deferred Tax Liabilities Deferred Expense Deferred Policy Acquisition Cost DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCost	1493727	usd
CY2023Q2	us-gaap	Deferred Tax Liabilities Deferred Expense Deferred Policy Acquisition Cost DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCost	1674785	usd
CY2024Q2	bnox	Deferred Tax Liabilities Accrued Interest Income DeferredTaxLiabilitiesAccruedInterestIncome	71	usd
CY2023Q2	bnox	Deferred Tax Liabilities Accrued Interest Income DeferredTaxLiabilitiesAccruedInterestIncome	65	usd
CY2024Q2	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	208005	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.007	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	320741	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	-0.003	pure
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	-242956	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	-0.011	pure
CY2024	bnox	Effective Income Tax Rate Reconciliation Project Costs EffectiveIncomeTaxRateReconciliationProjectCosts	-242820	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.016	pure
CY2023	bnox	Effective Income Tax Rate Reconciliation Project Costs EffectiveIncomeTaxRateReconciliationProjectCosts	-192410	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.009	pure
CY2024	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	51853	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	0.004	pure
CY2024	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-42212	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.003	pure
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	20692	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.001	pure
CY2024	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	3999422	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.257	pure
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4634968	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.215	pure
CY2024	bnox	Effective Income Tax Rate Reconciliation Decrease To State Tax Benefit EffectiveIncomeTaxRateReconciliationDecreaseToStateTaxBenefit	357738	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.023	pure
CY2023	bnox	Effective Income Tax Rate Reconciliation Decrease To State Tax Benefit EffectiveIncomeTaxRateReconciliationDecreaseToStateTaxBenefit	152402	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.007	pure
CY2024	bnox	Effective Income Tax Rate Reconciliation Other EffectiveIncomeTaxRateReconciliationOther	-8194	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.001	pure
CY2023	bnox	Effective Income Tax Rate Reconciliation Other EffectiveIncomeTaxRateReconciliationOther	-959	usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-87320	usd
CY2024	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.006	pure
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-139174	usd
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.006	pure
CY2024Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	646812	usd
CY2023Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	408919	usd
CY2023Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	21911771	usd
CY2024Q2	bnox	Deferred Tax Assets Capital Expenditures Not Deducted DeferredTaxAssetsCapitalExpendituresNotDeducted	1168484	usd
CY2024Q2	bnox	Deferred Tax Assets Tax Deferred Expense Provision For Leave DeferredTaxAssetsTaxDeferredExpenseProvisionForLeave	81513	usd
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	59688	usd
CY2024Q2	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	509498	usd
CY2023Q2	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	541841	usd
CY2024Q2	bnox	Deferred Tax Assets Warrant Costs DeferredTaxAssetsWarrantCosts	164725	usd
CY2024Q2	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	32061	usd
CY2023Q2	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	32061	usd
CY2023Q2	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	29224	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.003	pure
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	20692	usd
CY2024	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	3999422	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.257	pure
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4634968	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.215	pure
CY2024	bnox	Effective Income Tax Rate Reconciliation Decrease To State Tax Benefit EffectiveIncomeTaxRateReconciliationDecreaseToStateTaxBenefit	357738	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.023	pure
CY2023	bnox	Effective Income Tax Rate Reconciliation Decrease To State Tax Benefit EffectiveIncomeTaxRateReconciliationDecreaseToStateTaxBenefit	152402	usd
CY2024	bnox	Effective Income Tax Rate Reconciliation Other EffectiveIncomeTaxRateReconciliationOther	-8194	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.001	pure
CY2023	bnox	Effective Income Tax Rate Reconciliation Other EffectiveIncomeTaxRateReconciliationOther	-959	usd
CY2024	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.006	pure
CY2024Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	646812	usd
CY2023Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	408919	usd
CY2024Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	25723125	usd
CY2023Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	21911771	usd
CY2024Q2	bnox	Deferred Tax Assets Capital Expenditures Not Deducted DeferredTaxAssetsCapitalExpendituresNotDeducted	1168484	usd
CY2024Q2	bnox	Deferred Tax Assets Tax Deferred Expense Provision For Leave DeferredTaxAssetsTaxDeferredExpenseProvisionForLeave	81513	usd
CY2024Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	56122	usd
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	59688	usd
CY2024Q2	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	509498	usd
CY2023Q2	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	541841	usd
CY2024Q2	bnox	Deferred Tax Assets Warrant Costs DeferredTaxAssetsWarrantCosts	164725	usd
CY2024Q2	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	32061	usd
CY2023Q2	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	32061	usd
CY2023Q2	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	29224	usd
CY2024Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	69730	usd
CY2023Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	102756	usd
CY2023Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	24053587	usd
CY2024Q2	us-gaap	Deferred Tax Liabilities Deferred Expense Deferred Policy Acquisition Cost DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCost	1493727	usd
CY2023Q2	us-gaap	Deferred Tax Liabilities Deferred Expense Deferred Policy Acquisition Cost DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCost	1674785	usd
CY2024Q2	bnox	Deferred Tax Liabilities Accrued Interest Income DeferredTaxLiabilitiesAccruedInterestIncome	71	usd
CY2023Q2	bnox	Deferred Tax Liabilities Accrued Interest Income DeferredTaxLiabilitiesAccruedInterestIncome	65	usd
CY2024Q2	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	208005	usd
CY2024Q2	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1701803	usd
CY2023Q2	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1674850	usd
CY2024Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	27713807	usd
CY2024Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	963540	usd
CY2023Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	1102713	usd
CY2024Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	27700000	usd
CY2024Q2	bnox	Operating Loss Indefinite Carryforwards OperatingLossIndefiniteCarryforwards	1700000	usd
CY2024	bnox	Operating Loss Carryforwards Term OperatingLossCarryforwardsTerm	P20Y
CY2023	bnox	Operating Loss Carryforwards Term OperatingLossCarryforwardsTerm	P20Y
CY2024	bnox	Percentage Of Cumulative Change In Companys Ownership PercentageOfCumulativeChangeInCompanysOwnership	0.05	pure
CY2023Q2	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	29224	usd
CY2024Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	69730	usd
CY2023Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	102756	usd
CY2024Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	28452070	usd
CY2023Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	24053587	usd
CY2024Q2	us-gaap	Deferred Tax Liabilities Deferred Expense Deferred Policy Acquisition Cost DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCost	1493727	usd
CY2023Q2	us-gaap	Deferred Tax Liabilities Deferred Expense Deferred Policy Acquisition Cost DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCost	1674785	usd
CY2024Q2	bnox	Deferred Tax Liabilities Accrued Interest Income DeferredTaxLiabilitiesAccruedInterestIncome	71	usd
CY2023Q2	bnox	Deferred Tax Liabilities Accrued Interest Income DeferredTaxLiabilitiesAccruedInterestIncome	65	usd
CY2024Q2	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	208005	usd
CY2024Q2	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1701803	usd
CY2023Q2	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1674850	usd
CY2024Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	27713807	usd
CY2024Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	963540	usd
CY2023Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	1102713	usd
CY2024Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	27700000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	23500000	usd
CY2024Q2	bnox	Operating Loss Indefinite Carryforwards OperatingLossIndefiniteCarryforwards	1700000	usd
CY2024	bnox	Operating Loss Carryforwards Term OperatingLossCarryforwardsTerm	P20Y
CY2023	bnox	Operating Loss Carryforwards Term OperatingLossCarryforwardsTerm	P20Y
CY2024	bnox	Percentage Of Cumulative Change In Companys Ownership PercentageOfCumulativeChangeInCompanysOwnership	0.05	pure
CY2024	us-gaap	Payment For Management Fee PaymentForManagementFee	15000	usd
CY2024	bnox	Fundraising Proceeds Percentage FundraisingProceedsPercentage	0.05	pure
CY2023Q2	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	1900000	usd
CY2024Q2	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	600000	usd
CY2023Q2	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	2456199	usd
CY2023	bnox	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	592627	usd
CY2024Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	69730	usd
CY2023Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	102756	usd
CY2024Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	28452070	usd
CY2023Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	24053587	usd
CY2024Q2	us-gaap	Deferred Tax Liabilities Deferred Expense Deferred Policy Acquisition Cost DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCost	1493727	usd
CY2023Q2	us-gaap	Deferred Tax Liabilities Deferred Expense Deferred Policy Acquisition Cost DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCost	1674785	usd
CY2024Q2	bnox	Deferred Tax Liabilities Accrued Interest Income DeferredTaxLiabilitiesAccruedInterestIncome	71	usd
CY2023Q2	bnox	Deferred Tax Liabilities Accrued Interest Income DeferredTaxLiabilitiesAccruedInterestIncome	65	usd
CY2024Q2	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1701803	usd
CY2023Q2	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1674850	usd
CY2024Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	27713807	usd
CY2023Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	23481450	usd
CY2024Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	963540	usd
CY2023Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	1102713	usd
CY2024Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	27700000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	23500000	usd
CY2024Q2	bnox	Operating Loss Indefinite Carryforwards OperatingLossIndefiniteCarryforwards	1700000	usd
CY2024	bnox	Operating Loss Carryforwards Term OperatingLossCarryforwardsTerm	P20Y
CY2023	bnox	Operating Loss Carryforwards Term OperatingLossCarryforwardsTerm	P20Y
CY2024	bnox	Percentage Of Cumulative Change In Companys Ownership PercentageOfCumulativeChangeInCompanysOwnership	0.05	pure
CY2024	us-gaap	Payment For Management Fee PaymentForManagementFee	15000	usd
CY2024	bnox	Fundraising Proceeds Percentage FundraisingProceedsPercentage	0.05	pure
CY2023Q2	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	1900000	usd
CY2024Q2	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	600000	usd
CY2024Q2	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1701803	usd
CY2023Q2	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1674850	usd
CY2023Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	23481450	usd
CY2024Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	963540	usd
CY2023Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	1102713	usd
CY2023Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	23500000	usd
CY2024Q2	bnox	Operating Loss Indefinite Carryforwards OperatingLossIndefiniteCarryforwards	1700000	usd
CY2024	bnox	Operating Loss Carryforwards Term OperatingLossCarryforwardsTerm	P20Y
CY2023	bnox	Operating Loss Carryforwards Term OperatingLossCarryforwardsTerm	P20Y
CY2024	bnox	Percentage Of Cumulative Change In Companys Ownership PercentageOfCumulativeChangeInCompanysOwnership	0.05	pure
CY2024	us-gaap	Payment For Management Fee PaymentForManagementFee	15000	usd
CY2024	bnox	Fundraising Proceeds Percentage FundraisingProceedsPercentage	0.05	pure
CY2023Q2	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	1900000	usd
CY2024Q2	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	600000	usd
CY2024	bnox	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	-1868437	usd
CY2023	bnox	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	592627	usd
CY2024Q2	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	587762	usd
CY2023Q2	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	2456199	usd
CY2024	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 17. Commitments and Contingencies</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Ironwood Pharmaceuticals, Inc.</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">In January 2012, the Company entered into a research and license agreement with Ironwood Pharmaceuticals, Inc. (“Ironwood”) pursuant to which Ironwood was granted worldwide development and commercialization rights for BNC210. In November 2014, the parties mutually agreed to terminate this license agreement, reverting all rights to BNC210 back to the Company. The sole obligation to Ironwood is to pay Ironwood low to mid-single digit royalties on the net sales of BNC210, if commercialized. It is not practicable to estimate the future payments of any such royalties that may arise due to the stage of development of BNC210.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Severance Obligation</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The Company has a contingent liability in relation to the employment agreement with Dr. Spyros Papapetropoulos for severance pay of $787,500.</span></p>
CY2024	us-gaap	Payment For Management Fee PaymentForManagementFee	15000	usd
CY2024	bnox	Fundraising Proceeds Percentage FundraisingProceedsPercentage	0.05	pure
CY2023Q2	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	1900000	usd
CY2023Q2	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	2456199	usd
CY2022Q2	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	1863572	usd
CY2024	bnox	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	-1868437	usd
CY2023Q2	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	2456199	usd
CY2024	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 17. Commitments and Contingencies</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Ironwood Pharmaceuticals, Inc.</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">In January 2012, the Company entered into a research and license agreement with Ironwood Pharmaceuticals, Inc. (“Ironwood”) pursuant to which Ironwood was granted worldwide development and commercialization rights for BNC210. In November 2014, the parties mutually agreed to terminate this license agreement, reverting all rights to BNC210 back to the Company. The sole obligation to Ironwood is to pay Ironwood low to mid-single digit royalties on the net sales of BNC210, if commercialized. It is not practicable to estimate the future payments of any such royalties that may arise due to the stage of development of BNC210.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Severance Obligation</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The Company has a contingent liability in relation to the employment agreement with Dr. Spyros Papapetropoulos for severance pay of $787,500.</span></p>
CY2024	dei	Entity Registrant Name EntityRegistrantName	BIONOMICS LIMITED/FI
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q2	us-gaap	Common Stock Value CommonStockValue		usd
CY2023Q2	us-gaap	Common Stock Value CommonStockValue		usd
CY2024Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue
CY2023Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue
CY2024	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2023Q2	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	2456199	usd
CY2023	bnox	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	592627	usd
CY2024Q2	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	587762	usd
CY2024	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 17. Commitments and Contingencies</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Ironwood Pharmaceuticals, Inc.</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">In January 2012, the Company entered into a research and license agreement with Ironwood Pharmaceuticals, Inc. (“Ironwood”) pursuant to which Ironwood was granted worldwide development and commercialization rights for BNC210. In November 2014, the parties mutually agreed to terminate this license agreement, reverting all rights to BNC210 back to the Company. The sole obligation to Ironwood is to pay Ironwood low to mid-single digit royalties on the net sales of BNC210, if commercialized. It is not practicable to estimate the future payments of any such royalties that may arise due to the stage of development of BNC210.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Severance Obligation</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The Company has a contingent liability in relation to the employment agreement with Dr. Spyros Papapetropoulos for severance pay of $787,500.</span></p>
CY2024	dei	Entity Registrant Name EntityRegistrantName	BIONOMICS LIMITED/FI
CY2024	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	00-0000000
CY2023Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding		usd
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q2	us-gaap	Common Stock Value CommonStockValue		usd
CY2023Q2	us-gaap	Common Stock Value CommonStockValue		usd
CY2024Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue
CY2023Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue
CY2024	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1468735424	shares
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1797606532	shares
CY2024	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2023	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants		usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023Q2	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent		usd
CY2024Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	1463421	usd
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P100000Y
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit		usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential		usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions		pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments		pure
CY2023Q2	bnox	Deferred Tax Assets Warrant Costs DeferredTaxAssetsWarrantCosts		usd
CY2024Q2	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	587762	usd
CY2023Q2	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	2456199	usd
CY2024	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 17. Commitments and Contingencies</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Ironwood Pharmaceuticals, Inc.</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">In January 2012, the Company entered into a research and license agreement with Ironwood Pharmaceuticals, Inc. (“Ironwood”) pursuant to which Ironwood was granted worldwide development and commercialization rights for BNC210. In November 2014, the parties mutually agreed to terminate this license agreement, reverting all rights to BNC210 back to the Company. The sole obligation to Ironwood is to pay Ironwood low to mid-single digit royalties on the net sales of BNC210, if commercialized. It is not practicable to estimate the future payments of any such royalties that may arise due to the stage of development of BNC210.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Severance Obligation</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The Company has a contingent liability in relation to the employment agreement with Dr. Spyros Papapetropoulos for severance pay of $787,500.</span></p>
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q2	us-gaap	Common Stock Value CommonStockValue		usd
CY2023Q2	us-gaap	Common Stock Value CommonStockValue		usd
CY2024Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue
CY2023Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue
CY2024	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1468735424	shares
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1797606532	shares
CY2024	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2023	bnox	Proceeds From Saleof Sharesand Prefunded Warrants ProceedsFromSaleofSharesandPrefundedWarrants		usd
CY2024	bnox	Proceeds From Sale Of Ads Shares ProceedsFromSaleOfADSShares		usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P100000Y
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit		usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential		usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions		pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments		pure
CY2023Q2	bnox	Deferred Tax Assets Warrant Costs DeferredTaxAssetsWarrantCosts		usd
CY2024Q2	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes		usd
CY2023Q2	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther		usd
CY2023	bnox	Operating Loss Carryforwards Expiration Year OperatingLossCarryforwardsExpirationYear	2033
CY2024	dei	Amendment Flag AmendmentFlag	false
CY2024	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2024	dei	Entity Central Index Key EntityCentralIndexKey	0001191070
CY2024	dei	Entity Registrant Name EntityRegistrantName	BIONOMICS LIMITED/FI
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q2	us-gaap	Common Stock Value CommonStockValue		usd
CY2023Q2	us-gaap	Common Stock Value CommonStockValue		usd
CY2024Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue
CY2023Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue
CY2024	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1468735424	shares
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1797606532	shares
CY2024	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2023	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants		usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023Q2	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent		usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P100000Y
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit		usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential		usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions		pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments		pure
CY2023Q2	bnox	Deferred Tax Assets Warrant Costs DeferredTaxAssetsWarrantCosts		usd
CY2024Q2	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes		usd
CY2023Q2	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther		usd
CY2023	bnox	Operating Loss Carryforwards Expiration Year OperatingLossCarryforwardsExpirationYear	2033
CY2024	dei	Amendment Flag AmendmentFlag	false
CY2024	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1468735424	shares
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1797606532	shares
CY2024	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2023	bnox	Proceeds From Saleof Sharesand Prefunded Warrants ProceedsFromSaleofSharesandPrefundedWarrants		usd
CY2024	bnox	Proceeds From Sale Of Ads Shares ProceedsFromSaleOfADSShares		usd
CY2023	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants		usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2024Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	1463421	usd
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P100000Y
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit		usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2023Q2	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther		usd
CY2023	bnox	Operating Loss Carryforwards Expiration Year OperatingLossCarryforwardsExpirationYear	2033
CY2024	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2024	dei	Entity Central Index Key EntityCentralIndexKey	0001191070
CY2024Q2	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes		usd
CY2023Q2	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther		usd
CY2023	bnox	Operating Loss Carryforwards Expiration Year OperatingLossCarryforwardsExpirationYear	2033
CY2024	dei	Amendment Flag AmendmentFlag	false
CY2024	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2024	dei	Entity Central Index Key EntityCentralIndexKey	0001191070

Files In Submission

Name	View Source	Status
0001213900-24-082909-index-headers.html	Edgar Link	pending
0001213900-24-082909-index.html	Edgar Link	pending
0001213900-24-082909.txt	Edgar Link	pending
0001213900-24-082909-xbrl.zip	Edgar Link	pending
bnox-20240630.xsd	Edgar Link	pending
ea0213573-10k_bionomic.htm	Edgar Link	pending
ea021357301ex14-1_bionomic.htm	Edgar Link	pending
ea021357301ex19-1_bionomic.htm	Edgar Link	pending
ea021357301ex31-1_bionomic.htm	Edgar Link	pending
ea021357301ex31-2_bionomic.htm	Edgar Link	pending
ea021357301ex32-1_bionomic.htm	Edgar Link	pending
ea021357301ex32-2_bionomic.htm	Edgar Link	pending
ea021357301ex97-1_bionomic.htm	Edgar Link	pending
ex14-1_001.jpg	Edgar Link	pending
ex19-1_001.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
image_005.jpg	Edgar Link	pending
bnox-20240630_def.xml	Edgar Link	unprocessable
bnox-20240630_lab.xml	Edgar Link	unprocessable
bnox-20240630_pre.xml	Edgar Link	unprocessable
bnox-20240630_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
ea0213573-10k_bionomic_htm.xml	Edgar Link	completed
0001213900-24-082909-index-headers.html	Edgar Link	pending
0001213900-24-082909-index.html	Edgar Link	pending
0001213900-24-082909.txt	Edgar Link	pending
0001213900-24-082909-xbrl.zip	Edgar Link	pending
bnox-20240630.xsd	Edgar Link	pending
ea0213573-10k_bionomic.htm	Edgar Link	pending
ea021357301ex14-1_bionomic.htm	Edgar Link	pending
ea021357301ex19-1_bionomic.htm	Edgar Link	pending
ea021357301ex31-1_bionomic.htm	Edgar Link	pending
ea021357301ex31-2_bionomic.htm	Edgar Link	pending
ea021357301ex32-1_bionomic.htm	Edgar Link	pending
ea021357301ex32-2_bionomic.htm	Edgar Link	pending
ea021357301ex97-1_bionomic.htm	Edgar Link	pending
ex14-1_001.jpg	Edgar Link	pending
ex19-1_001.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
image_005.jpg	Edgar Link	pending
image_006.jpg	Edgar Link	pending
image_007.jpg	Edgar Link	pending
image_008.jpg	Edgar Link	pending
image_009.jpg	Edgar Link	pending
image_010.jpg	Edgar Link	pending
image_011.jpg	Edgar Link	pending
image_012.jpg	Edgar Link	pending
image_013.jpg	Edgar Link	pending
image_014.jpg	Edgar Link	pending
image_015.jpg	Edgar Link	pending
image_016.jpg	Edgar Link	pending
image_017.jpg	Edgar Link	pending
image_018.jpg	Edgar Link	pending
image_019.jpg	Edgar Link	pending
image_020.jpg	Edgar Link	pending
image_021.jpg	Edgar Link	pending
image_022.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
bnox-20240630_lab.xml	Edgar Link	unprocessable
bnox-20240630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
image_006.jpg	Edgar Link	pending
image_007.jpg	Edgar Link	pending
image_008.jpg	Edgar Link	pending
image_009.jpg	Edgar Link	pending
image_010.jpg	Edgar Link	pending
image_011.jpg	Edgar Link	pending
image_012.jpg	Edgar Link	pending
image_013.jpg	Edgar Link	pending
image_014.jpg	Edgar Link	pending
image_015.jpg	Edgar Link	pending
image_016.jpg	Edgar Link	pending
image_017.jpg	Edgar Link	pending
image_018.jpg	Edgar Link	pending
image_019.jpg	Edgar Link	pending
image_020.jpg	Edgar Link	pending
image_021.jpg	Edgar Link	pending
image_022.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
bnox-20240630_cal.xml	Edgar Link	unprocessable
ea0213573-10k_bionomic_htm.xml	Edgar Link	completed
bnox-20240630_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NEUP
Neuphoria Therapeutics Inc. Stock $neup

2024 Q3 Form 10-K Financial Statement

#000121390024082909 Filed on September 30, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NEUP Neuphoria Therapeutics Inc. Stock $neup

2024 Q3 Form 10-K Financial Statement

#000121390024082909 Filed on September 30, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NEUP
Neuphoria Therapeutics Inc. Stock $neup